166
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Efficacy of Topical Nepafenac 0.3% in the Management of Postoperative Cystoid Macular Edema

, , , , , & ORCID Icon show all
Pages 1067-1074 | Published online: 06 Nov 2020

References

  • Gass JD, Norton EW. Fluorescein studies of patients with macular edema and papilledema following cataract extraction. Trans Am Ophthalmol Soc. 1966;64:232–249.
  • Irvine AR. Cystoid maculopathy. Surv Ophthalmol. 1976;21:1–17. doi:10.1016/0039-6257(76)90045-X
  • Loewenstein A, Zur D. Postsurgical cystoid macular edema. Dev Ophthalmol. 2010;47:148–159.
  • Chu CJ, Johnston RL, Buscombe C, Sallam AB, Mohamed Q, Yang YC; United Kingdom Pseudophakic Macular Edema Study Group. Risk factors and incidence of macular edema after cataract surgery: a database study of 81984 eyes. Ophthalmology. 2016;123(2):316–323. doi:10.1016/j.ophtha.2015.10.001
  • Shimura M, Yasuda K, Nakazawa T, et al. Panretinal photocoagulation induces pro-inflammatory cytokines and macular thickening in high-risk proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2009;247:1617–1624.
  • Rossetti L, Autelitano A. Cystoid macular edema following cataract surgery. Curr Opin Ophthalmol. 2000;11:65–72. doi:10.1097/00055735-200002000-00010
  • Zur D, Loewenstein A. Postsurgical cystoid macular edema. Dev Ophthalmol. 2017;58:178–190.
  • Walters T, Raizman M, Ernest P, et al. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg. 2007;33:1539–1545.
  • Singh RP, Lehmann R, Martel J, et al. Nepafenac 0.3% after cataract surgery in patients with diabetic retinopathy: results of 2 randomized phase 3 studies. Ophthalmology. 2017;124(6):776–785. doi:10.1016/j.ophtha.2017.01.036
  • Kusbeci T, Eryigit L, Yavas G, Inan UU. Evaluation of cystoid macular edema using optical coherence tomography and fundus fluorescein angiography after uncomplicated phacoemulsification surgery. Curr Eye Res. 2012;37(4):327–333. doi:10.3109/02713683.2011.635402
  • Hariprasad SM, Callanan D, Gainey S, et al. Cystoid and diabetic macular edema treated with nepafenac 0.1%. J Ocul Pharmacol Ther. 2007;23:585–590. doi:10.1089/jop.2007.0062
  • Prausnitz MR, Noonan JS. Permeability of cornea, sclera and conjunctiva: a literature analysis for drug delivery to the eye. J Pharm Sci. 1998;87(12):1479–1488.
  • Available from: https://www.ema.europa.eu/en/documents/product-information/nevanac-epar-product-information_en.pdf. Accessed October 13, 2020.
  • Shapiro SS, Wilk MB. An analysis of variance test for normality (complete samples). Biometrika. 1965;52(3/4):591–611.
  • Razali NM, Wah YB. Comparisons of Shapiro-Wilk, Kolmogorov-Smirnov, Liliefors and Anderson-Darling test. J Sat Model Anal. 2011;2(1):21–33.
  • Doane DP, Seward LE. Measuring skewness. J Stat Educ. 2011;19(2):1–18. doi:10.1080/10691898.2011.11889611
  • Singh R, Alpern L, Jaffe GJ, et al. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clin Ophthalmol. 2012;6:1259–1269. doi:10.2147/OPTH.S31902
  • Pollack A, Staurenghi G, Sager D, et al. Prospective randomized clinical trial to evaluate the safety and efficacy of nepafenac treatment for the prevention of macular edema associated with cataract surgery in patients with diabetic retinopathy. Br J Ophthalmol. 2016.
  • Chastain JE, Sanders ME, Curtis MA, et al. Distribution of topical ocular nepafenac and its active metabolite amfenac to the posterior segment of the eye. Exp Eye Res. 2016;145:58–67. doi:10.1016/j.exer.2015.10.009
  • Afrashi F, Hashas AS, Shahbazov C, et al. Reliability of intravitreal nepafenac in rabbits. J Ocul Pharmacol Ther. 2015;31(1):43–50. doi:10.1089/jop.2014.0053
  • Scruggs J, Wallace T, Hanna C. Route of absorption of drug and ointment after application to the eye. Ann Ophthalmol. 1978;10(3):267–271.
  • Khurana RN, Palmer JD, Porco TC, Wieland MR. Dexamethasone intravitreal implant for pseudophakic cystoid macular edema in patients with diabetes. Ophthalmic Surg Lasers Imaging Retina. 2015;46(1):56–61. doi:10.3928/23258160-20150101-09
  • Ismail RA, Sallam A, Zambarakji HJ. Pseudophakic macular edema and oral acetazolamide: an optical coherence tomography measurable, dose-related response. Eur J Ophthalmol. 2008;18(6):1011–1013. doi:10.1177/112067210801800626
  • Wielders LH, Schouten JS, Aberle MR, et al. Treatment of cystoid macular edema after cataract surgery. J Cataract Refract Surg. 2017;43(2):276–284. doi:10.1016/j.jcrs.2016.06.041
  • Yüksel B, Karti Ö, Kusbeci T. Topical nepafenac for prevention of post-cataract surgery macular edema in diabetic patients: patient selection and perspectives. Clin Ophthalmol. 2017;11(11):2183–2190. doi:10.2147/OPTH.S132810
  • Rho DS. Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. J Cataract Refract Surg. 2003;29(12):2378–2384.
  • Warren KA, Bahrani H, Fox JE. NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid macular edema. Retina. 2010;30(2):260–266. doi:10.1097/IAE.0b013e3181b8628e